Latest

neuropharmacology

·March 6, 2025·2 min read

Long-Term NSAID Use Linked to Lower Dementia Risk

A new study finds that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a lower risk of developing dementia. Researchers followed 11,745 adults over 14.5 years and found that those who used NSAIDs long-term had a 12% reduced dementia risk.

Featured Neuroscience Psychology

·February 14, 2025·6 min read

Prozac Shows Promise in Fighting Infections & Sepsis

New research suggests that fluoxetine, commonly used as an antidepressant, may also help protect against infections and sepsis. Scientists found that the drug has antimicrobial properties and helps regulate the immune response, reducing the risk of tissue and organ damage.

Featured Neuroscience

·February 12, 2025·7 min read

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption. Researchers found that weekly injections of semaglutide decreased alcohol cravings, drinking quantity, and heavy drinking days in adults with alcohol use disorder. Participants receiving semaglutide consumed less alcohol in a controlled lab setting and reported reduced cravings compared to those receiving a placebo.

Featured Neuroscience Pain

·February 6, 2025·6 min read

How CBD Modulates THC’s Impact on the Brain

Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis. Unlike THC, which fully activates the receptor and causes side effects like memory loss and addiction, CBD acts as a modulator, fine-tuning receptor activity.

Featured Neurology Neuroscience

·January 21, 2025·6 min read

Antibiotics and Other Drugs May Reduce Dementia Risk

A study analyzing data from over 130 million individuals found that antibiotics, antivirals, vaccines, and anti-inflammatory medications are associated with a reduced risk of dementia. This supports the idea that infections and inflammation contribute to dementia and highlights the potential of repurposing existing drugs for prevention or treatment.

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

This shows a man's head and the covid virus.

Featured Neuroscience

·January 6, 2025·5 min read

Extended Paxlovid May Relieve Long Covid Symptoms

Extended courses of Paxlovid may alleviate symptoms in some patients with long Covid, though its effectiveness varies widely. Of 13 patients studied, five experienced sustained improvements, while others reported temporary or no benefits.

Featured Neurology Neuroscience

·January 3, 2025·5 min read

Ketamine Offers Hope for Parkinson’s Treatment-Linked Dyskinesia

Researchers have uncovered a new understanding of levodopa-induced dyskinesia, a common side effect in Parkinson’s patients, revealing that the motor cortex disconnects rather than directly causing these movements.

Featured Neurology Neuroscience

·November 26, 2024·3 min read

Alzheimer’s Drug Shrinks Brain Volume by Removing Amyloid Plaques

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage. Researchers analyzed data from multiple trials and coined the term "amyloid-removal-related pseudo-atrophy" (ARPA) to describe this phenomenon.

Featured Genetics Neurology Neuroscience

·November 25, 2024·4 min read

New Platform Overcomes Blood-Brain Barrier for Drug Delivery

Researchers have developed a breakthrough system to deliver large therapeutic molecules into the brain, overcoming the challenges of the blood-brain barrier.

This shows chemical imaging of the microbiome.

Featured Neurology Neuroscience

·November 21, 2024·5 min read

Parkinson’s Medication Alters Microbiome, Induces Iron Deficiency

The Parkinson's drug entacapone disrupts the gut microbiome by inducing iron deficiency, favoring the growth of potentially harmful bacteria like E. coli. Using advanced molecular techniques, researchers identified that entacapone interferes with iron availability, a critical resource for many gut microbes.

Featured Neurology Neuroscience

·November 18, 2024·4 min read

Repurposed Multiple Sclerosis Drug May Improve Memory

Fampridine, used for improving walking in multiple sclerosis, may also enhance working memory in individuals with schizophrenia or depression. A study found that the drug significantly improved working memory in participants with initially poor performance, but had no effect on those with strong baseline memory.

1 … 7 8 9 10 11 … 81

neuropharmacology

Long-Term NSAID Use Linked to Lower Dementia Risk

Prozac Shows Promise in Fighting Infections & Sepsis

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

How CBD Modulates THC’s Impact on the Brain

Antibiotics and Other Drugs May Reduce Dementia Risk

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

Extended Paxlovid May Relieve Long Covid Symptoms

Ketamine Offers Hope for Parkinson’s Treatment-Linked Dyskinesia

Alzheimer’s Drug Shrinks Brain Volume by Removing Amyloid Plaques

New Platform Overcomes Blood-Brain Barrier for Drug Delivery

Parkinson’s Medication Alters Microbiome, Induces Iron Deficiency

Repurposed Multiple Sclerosis Drug May Improve Memory

How Scientists Cracked the Ketamine Code for Depression

Brain Prioritizes “Sound Offsets” During Hearing Repair

Glucose Levels Signal the Growth of Myelin

Why Your Brain “Dreams” Even When You’re Awake

Subscribe